Guardant Health, Inc. (NASDAQ:GH) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 14.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 503,100 shares of the company's stock after buying an additional 64,700 shares during the period. Renaissance Technologies LLC owned approximately 0.41% of Guardant Health worth $15,370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Lord Abbett & CO. LLC bought a new stake in Guardant Health during the third quarter valued at about $15,624,000. Guyasuta Investment Advisors Inc. purchased a new stake in shares of Guardant Health during the 4th quarter worth approximately $206,000. Geode Capital Management LLC lifted its position in Guardant Health by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock valued at $64,754,000 after purchasing an additional 29,686 shares during the last quarter. Entropy Technologies LP purchased a new position in Guardant Health in the fourth quarter worth about $377,000. Finally, Raymond James Financial Inc. purchased a new position in Guardant Health during the fourth quarter worth $2,211,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Wall Street Analyst Weigh In

GH has been the subject of a number of recent analyst reports. Stifel Nicolaus boosted their target price on shares of Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Barclays dropped their target price on shares of Guardant Health from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Scotiabank lifted their price target on shares of Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday, February 24th. Canaccord Genuity Group lifted their price objective on Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a report on Monday, February 24th. Finally, Morgan Stanley increased their target price on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. Twenty equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $49.00.

Guardant Health Trading Down 0.5 %

Guardant Health stock traded down $0.21 during midday trading on Friday, reaching $44.97. 1,843,910 shares of the stock traded hands, compared to its average volume of 2,136,744. The firm has a market cap of $5.55 billion, a PE ratio of -12.63 and a beta of 1.45. The company has a 50-day simple moving average of $43.53 and a two-hundred day simple moving average of $36.21. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company had revenue of $201.81 million for the quarter, compared to analysts' expectations of $192.50 million. Equities research analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.